New hope for sarcoidosis patients: inhaled drug targets lung and heart strain
NCT ID NCT03814317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an inhaled medication called treprostinil in 5 people with sarcoidosis who also have lung scarring and high blood pressure in the lungs. The goal was to see if the drug could improve blood flow and heart function. Participants took the drug and were monitored with heart tests, walking tests, and breathing tests over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida, Division of Pulmonary and Critical Care Medicine
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Heart scans may unlock hidden risks in minority communities
- Can arm workouts boost oxygen use in lung disease?
- Can immune profiling unlock the hidden stages of tuberculosis?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- Virtual Nurse-Social worker team aims to ease symptoms for veterans with heart failure and COPD